The PiPS (Probiotics in Preterm Infants Study) Trial - Controlling the Confounding Factor of Cross-contamination Unveils Significant Benefits
- PMID: 28285299
The PiPS (Probiotics in Preterm Infants Study) Trial - Controlling the Confounding Factor of Cross-contamination Unveils Significant Benefits
Comment on
-
Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial.Lancet. 2016 Feb 13;387(10019):649-660. doi: 10.1016/S0140-6736(15)01027-2. Epub 2015 Nov 28. Lancet. 2016. PMID: 26628328 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources